Patent · US Active

Modified Vaccinia Ankara virus variant

US7923017B2 · kind B2 · utility

15Cited by

11References

16Claims

0Family size

Assignee

Bavarian Nordic A/S · DK

Inventors

Paul Chaplin · Munich, DE
Paul Howley · Scone, AU
Christine Meisinger-Henschel · Schwanau, DE

Key dates

Filing date	Oct 26, 2007
Grant date	Apr 12, 2011
Priority date	—
Expiry date	Mar 23, 2029

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2740/16322
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention provides an attenuated virus, which is derived from Modified Vaccinia Ankara virus, wherein the MVA-BN virus, or a derivative thereof, induces at least substantially the same level of immunity in vaccinia virus prime/vaccina virus boost regimes when compared to DNA prime/vaccinia virus boost regimes. It further describes recombinant viruses derived from this virus and the use of the virus, or its recombinants, as a medicament or vaccine. A method is provided for inducing an immune response in individuals who may be immune-compromised, receiving antiviral therapy, or have a pre-existing immunity to the vaccine virus.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.